MX2007010129A - Derivados de beta-ciclodextrina como agentes antibacteriales. - Google Patents
Derivados de beta-ciclodextrina como agentes antibacteriales.Info
- Publication number
- MX2007010129A MX2007010129A MX2007010129A MX2007010129A MX2007010129A MX 2007010129 A MX2007010129 A MX 2007010129A MX 2007010129 A MX2007010129 A MX 2007010129A MX 2007010129 A MX2007010129 A MX 2007010129A MX 2007010129 A MX2007010129 A MX 2007010129A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- lower alkyl
- aryl
- aralkyl
- aminoalkyl
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title claims abstract description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 90
- 150000001875 compounds Chemical class 0.000 claims description 46
- 125000003118 aryl group Chemical group 0.000 claims description 45
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 33
- 229910052717 sulfur Inorganic materials 0.000 claims description 24
- 241000894006 Bacteria Species 0.000 claims description 21
- 125000000623 heterocyclic group Chemical group 0.000 claims description 21
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 16
- 230000003115 biocidal effect Effects 0.000 claims description 15
- 208000035143 Bacterial infection Diseases 0.000 claims description 13
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 13
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 11
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229940088710 antibiotic agent Drugs 0.000 abstract description 25
- 244000052616 bacterial pathogen Species 0.000 abstract description 7
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 abstract description 3
- 125000004122 cyclic group Chemical group 0.000 abstract description 3
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 238000000034 method Methods 0.000 description 24
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 11
- 229960003085 meticillin Drugs 0.000 description 11
- 239000000203 mixture Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 229960005091 chloramphenicol Drugs 0.000 description 6
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 6
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 6
- 229960001180 norfloxacin Drugs 0.000 description 6
- 229930195708 Penicillin V Natural products 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 108010059993 Vancomycin Proteins 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940056367 penicillin v Drugs 0.000 description 5
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 5
- 229960000707 tobramycin Drugs 0.000 description 5
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 5
- 229960003165 vancomycin Drugs 0.000 description 5
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 5
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000194031 Enterococcus faecium Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193410 Bacillus atrophaeus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64784105P | 2005-01-28 | 2005-01-28 | |
| PCT/US2006/002801 WO2006083678A2 (en) | 2005-01-28 | 2006-01-27 | β-CYCLODEXTRIN DERIVATIVES AS ANTIBACTERIAL AGENTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2007010129A true MX2007010129A (es) | 2007-11-16 |
Family
ID=36777776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2007010129A MX2007010129A (es) | 2005-01-28 | 2006-01-27 | Derivados de beta-ciclodextrina como agentes antibacteriales. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7737132B2 (enExample) |
| EP (1) | EP1846006A4 (enExample) |
| JP (1) | JP2008528761A (enExample) |
| KR (1) | KR20070101347A (enExample) |
| CN (1) | CN101151037A (enExample) |
| AU (1) | AU2006211173A1 (enExample) |
| CA (1) | CA2596026A1 (enExample) |
| IL (1) | IL184844A0 (enExample) |
| MX (1) | MX2007010129A (enExample) |
| RU (1) | RU2007133709A (enExample) |
| WO (1) | WO2006083678A2 (enExample) |
| ZA (1) | ZA200706191B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120277184A1 (en) * | 2004-01-29 | 2012-11-01 | Innovative biologics, Inc | Blockers of pore-forming virulence factors and their use as anti-infectives |
| WO2006001844A2 (en) * | 2004-01-29 | 2006-01-05 | Pinnacle Pharmaceuticals | β-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST ANTHRAX LETHAL TOXIN |
| JP5098015B2 (ja) * | 2005-01-13 | 2012-12-12 | 国立大学法人 名古屋工業大学 | 菌体膜傷害性・抗菌性物質とその利用方法 |
| EP1846006A4 (en) * | 2005-01-28 | 2011-04-20 | Pinnacle Pharmaceuticals Inc | BETA-CYCLODEXTRIN DERIVATIVES AS ANTIBACTERIAL AGENTS |
| WO2008105822A2 (en) * | 2006-08-30 | 2008-09-04 | Research Foundation Of The City University Of New York | Antimicrobial compositions |
| WO2009058327A1 (en) * | 2007-10-30 | 2009-05-07 | Pinnacle Pharmaceuticals, Inc. | Cyclodextrin derivatives as potentiators for antibiotics |
| JP5364923B2 (ja) * | 2009-01-28 | 2013-12-11 | 学校法人福岡大学 | 多機能性シクロデキストリン誘導体、その包接化合物およびそれらの製造方法。 |
| GB201114459D0 (en) | 2011-08-22 | 2011-10-05 | Isis Innovation | Anti-bacterial compounds |
| EP2690105A1 (en) * | 2012-07-24 | 2014-01-29 | Centre National De La Recherche Scientifique | Mannose derivatives, a process for preparing the same and their uses as a drug |
| JP6249208B2 (ja) * | 2012-10-31 | 2017-12-20 | 国立大学法人 名古屋工業大学 | 糖誘導体及びそれを用いた抗菌剤 |
| CN103497275B (zh) * | 2013-08-09 | 2015-12-23 | 华北电力大学（保定） | 一种抗菌、抗病毒胍盐星形聚合物及其制备方法和应用 |
| JP6624422B2 (ja) * | 2014-07-25 | 2019-12-25 | 国立大学法人 名古屋工業大学 | 糖誘導体またはその塩、それらを用いた抗菌剤または抗菌活性増強剤、およびこれらを合成する試薬、試薬を用いたこれらの製造方法 |
| CN106734046A (zh) * | 2015-11-20 | 2017-05-31 | 南京科技职业学院 | 一种焦化污泥无害化处理方法 |
| JP6734510B2 (ja) | 2016-09-13 | 2020-08-05 | 国立大学法人 名古屋工業大学 | 糖誘導体またはその塩、それらを用いた抗菌剤または抗菌活性増強剤 |
| WO2018127819A1 (en) | 2017-01-03 | 2018-07-12 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
| WO2018178902A1 (en) | 2017-03-28 | 2018-10-04 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto |
| KR101967326B1 (ko) * | 2017-10-30 | 2019-08-13 | 한남대학교 산학협력단 | 양이온성 사이클로덱스트린 유도체 및 이를 이용한 약물전달 시스템 |
| US12460050B2 (en) | 2017-11-15 | 2025-11-04 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing hyperbranched compounds as antibacterial scaffolds and methods pertaining thereto |
| AU2019231712B2 (en) * | 2018-03-06 | 2025-04-10 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
| CA3124673A1 (en) | 2018-12-28 | 2020-07-02 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto |
| TWI774079B (zh) * | 2020-10-05 | 2022-08-11 | 逢興生物科技股份有限公司 | 環糊精用於製造抑制口腔細菌生長的組合物的用途 |
| CN112516003A (zh) * | 2020-12-18 | 2021-03-19 | 上海杜可生物科技有限公司 | 环糊精用于抑制口腔细菌生长的组合物的用途 |
| US11856953B2 (en) | 2021-03-11 | 2024-01-02 | Nano And Advanced Materials Institute Limited | Launderable bactericidal and virucidal fabric finish |
| CN116284506B (zh) * | 2023-03-22 | 2023-12-08 | 江南大学 | 一种γ-环糊精-香叶醇衍生物及其制备方法与应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US576017A (en) * | 1897-01-26 | Game-counter | ||
| JPS5211348B2 (enExample) | 1972-12-23 | 1977-03-30 | ||
| JPS5311000B2 (enExample) | 1974-04-18 | 1978-04-18 | ||
| DE2425663A1 (de) | 1974-05-28 | 1975-12-04 | Tanabe Seiyaku Co | Cyclodextrinderivate sowie verfahren zu ihrer herstellung |
| JPS51142088A (en) | 1975-05-29 | 1976-12-07 | Tanabe Seiyaku Co Ltd | Aminocyclodextrin derivatives and their prepapation. |
| JPS52138580A (en) * | 1976-05-14 | 1977-11-18 | Tanabe Seiyaku Co Ltd | Cyclodextrin derivatives |
| JPS5349089A (en) | 1976-10-15 | 1978-05-04 | Tanabe Seiyaku Co Ltd | Cyclic polysaccaride compounds and their preparatin |
| US4247535A (en) | 1979-11-05 | 1981-01-27 | American Cyanamid Company | Modified cyclodextrin sulfate salts as complement inhibitors |
| US4258180A (en) | 1979-11-05 | 1981-03-24 | American Cyanamid Company | C6-Modified cyclodextrin sulfate salts as complement inhibitors |
| DE3744742C2 (enExample) * | 1986-10-31 | 1993-03-11 | Director-General Of Agency Of Industrial Science And Technology, Tokio/Tokyo, Jp | |
| JPS63117003A (ja) * | 1986-10-31 | 1988-05-21 | Agency Of Ind Science & Technol | シクロデキストリン誘導体 |
| JPS63144329A (ja) * | 1986-12-09 | 1988-06-16 | Agency Of Ind Science & Technol | 色素とシクロデキストリン誘導体の包接体の有機超薄膜とその製造方法 |
| JPH0375634A (ja) | 1989-08-17 | 1991-03-29 | Agency Of Ind Science & Technol | 光学記憶媒体 |
| DK0447171T3 (da) | 1990-03-15 | 1994-12-12 | Tanabe Seiyaku Co | Polysulfat af cyclodextrinderivat og fremgangsmåde til fremstilling deraf |
| JPH04136001A (ja) * | 1990-09-27 | 1992-05-11 | Tanabe Seiyaku Co Ltd | β―シクロデキストリン・スルホンアミド誘導体のポリ硫酸エステル及びその製法 |
| JPH04227602A (ja) * | 1990-03-15 | 1992-08-17 | Tanabe Seiyaku Co Ltd | アミノ−β−シクロデキストリン誘導体のポリ硫酸エステル及びその製法 |
| JPH04226502A (ja) * | 1990-09-27 | 1992-08-17 | Tanabe Seiyaku Co Ltd | アシルアミノシクロデキストリン誘導体のポリ硫酸エステル及びその製法 |
| FR2669535A1 (fr) | 1990-11-26 | 1992-05-29 | Medgenix Group Sa | Utilisation a titre de medicament de macromolecules polysulfonees. |
| FR2681868A1 (fr) * | 1991-09-30 | 1993-04-02 | Sederma Sa | Nouvelles substances amphiphiles derivees de cyclodextrines et leur utilisation dans des compositions cosmetiques. |
| DE4136325A1 (de) | 1991-11-05 | 1993-05-13 | Hoechst Ag | Cyclodextrinderivate als adsorptionsmittel fuer gallensaeure, mit gallensaeuren beladene cyclodextrinderivate und verfahren zu deren herstellung sowie deren anwendung als arzneimittel |
| HUT63704A (en) | 1991-11-20 | 1993-09-28 | Forte Fotokemiai Ipar | Method for accelerating development of photo-materials |
| JPH0665307A (ja) | 1992-06-17 | 1994-03-08 | Sankyo Co Ltd | シクロデキストリン誘導体 |
| ES2053399B1 (es) | 1993-01-11 | 1995-02-16 | Univ Madrid Complutense | Procedimiento para la obtencion de derivados de beta-ciclodextrina. |
| US5959089A (en) | 1993-07-19 | 1999-09-28 | Hannessian; Stephen | Amino-cyclodextrin syntheses |
| US5599912A (en) | 1993-09-10 | 1997-02-04 | Coretech, Inc. | Compounds and methods for suppressing an immune response to sulfomethoxozale containing substances |
| GB9325330D0 (en) | 1993-12-10 | 1994-02-16 | Univ Toronto | Fluorocyclodextrin drug delivery system |
| FR2714067B1 (fr) * | 1993-12-22 | 1996-01-12 | Commissariat Energie Atomique | Nouveaux dérivés de cyclodextrines, utilisables en particulier pour solubiliser des composés chimiques hydrophobes tels que des médicaments, et leur procédé de préparation. |
| FR2713934B1 (fr) | 1993-12-22 | 1996-01-12 | Commissariat Energie Atomique | Utilisation de cyclodextrines aminées pour la solubilisation aqueuse de composés hydrophobes, en particulier de molécules pharmaceutiquement actives. |
| DE4418842A1 (de) | 1994-05-30 | 1995-12-07 | Hoechst Ag | Verwendung ringförmiger Oligosaccharide als Ladungssteuermittel |
| DE4429229A1 (de) | 1994-08-18 | 1996-02-22 | Consortium Elektrochem Ind | Cyclodextrinderivate mit mindestens einem stickstoffhaltigen Heterozyklus, ihre Herstellung und Verwendung |
| DE19517034A1 (de) | 1995-05-10 | 1996-11-14 | Hoechst Ag | Verwendung von Einschluß-Verbindungen ringförmiger Polysaccharide als Ladungssteuermittel |
| DE19520967A1 (de) | 1995-06-08 | 1996-12-12 | Consortium Elektrochem Ind | Textiles Material oder Leder, welches mit Cyclodextrinderivaten mit mindestens einem stickstoffhaltigen Heterozyklus ausgerüstet ist |
| DE19520989A1 (de) | 1995-06-08 | 1996-12-12 | Consortium Elektrochem Ind | Cyclodextrinmodifizierte Polymere |
| FR2736056B1 (fr) | 1995-06-29 | 1997-08-08 | Commissariat Energie Atomique | Derives de cyclodextrines, leur preparation et leur utilisation pour incorporer des molecules hydrophobes dans des systemes de tensioactifs organises |
| US5834446A (en) * | 1996-06-21 | 1998-11-10 | Queen's University At Kingston | Nerve process growth modulators |
| JPH1060006A (ja) | 1996-08-27 | 1998-03-03 | Kikkoman Corp | 非還元末端アジド化アセチルマルトオリゴシルブロマイドの製造法 |
| FR2767834B1 (fr) | 1997-08-29 | 1999-12-03 | Inst Francais Du Petrole | Mono et di-derives de cyclodextrines, leurs synthese et purification et leur utilisation en support |
| US6180356B1 (en) | 1998-03-06 | 2001-01-30 | The Research Foundation Of State University Of Ny | Membrane pore inhibiting agents for treating infection |
| FR2776666B1 (fr) | 1998-03-31 | 2002-09-06 | Commissariat Energie Atomique | Complexes d'inclusion dans des cyclodextrines d'isothiocyanates organiques, en particulier bacteriostatiques, bactericides et/ou fongicides ou de leurs precurseurs naturels, et leur preparation |
| FR2792942B1 (fr) | 1999-04-29 | 2001-06-08 | Commissariat Energie Atomique | Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes |
| TWI242015B (en) | 1999-11-29 | 2005-10-21 | Akzo Nobel Nv | 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
| CA2406823A1 (en) | 2000-04-28 | 2001-11-08 | Lawrence John Penkler | Amphiphilic macrocyclic derivatives and their analogues |
| SG114468A1 (en) | 2000-06-23 | 2005-09-28 | Univ Singapore | Separation materials for chromatography and electrophoresis applications comprising cyclodextrins cross-linked and chemically bonded to a support via urethane linkages |
| WO2002077000A2 (en) | 2001-03-23 | 2002-10-03 | University College Dublin | Macrocyclic oligosaccharide derivatives which form manoscale assemblies |
| DE60135540D1 (de) * | 2001-03-27 | 2008-10-09 | Samsung Electronics Co Ltd | noporen |
| US6632748B2 (en) | 2001-03-27 | 2003-10-14 | Samsung Electronics Co., Ltd. | Composition for preparing substances having nano-pores |
| FR2843397B1 (fr) | 2002-08-06 | 2004-10-15 | Chelator | Nouveaux derives de cyclodextrines, leur procede de preparation et leurs applications |
| KR100533538B1 (ko) | 2002-12-03 | 2005-12-05 | 삼성전자주식회사 | 새로운 기공형성물질을 포함하는 다공성 층간 절연막을형성하기 위한 조성물 |
| JP4675233B2 (ja) * | 2003-03-27 | 2011-04-20 | ナノデックス株式会社 | 新規シクロデキストリン誘導体 |
| FR2852959B1 (fr) | 2003-03-28 | 2008-02-15 | Centre Nat Rech Scient | Nouveaux derives de cyclodextrines, leur procede de preparation et leur utilisation notamment pour solubilisation de substances pharmacologiquement actives |
| WO2005011710A1 (en) * | 2003-07-28 | 2005-02-10 | The Board Of Trustees Of The University Of Illinois | Per-6-aminosubstituted-deoxy-cyclodextrins to treat alzheimer’s diseases |
| FR2861396B1 (fr) | 2003-10-24 | 2005-12-16 | Commissariat Energie Atomique | Derives amphiphiles de cyclodextrines,leur procede de preparation et leurs utilisations |
| WO2006001844A2 (en) * | 2004-01-29 | 2006-01-05 | Pinnacle Pharmaceuticals | β-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST ANTHRAX LETHAL TOXIN |
| JP2005290066A (ja) | 2004-03-31 | 2005-10-20 | Nihon Hels Industry Corp | シクロデキストリンポリマーおよびこれを利用した水の汚染度の測定方法 |
| EP1817348B1 (en) | 2004-09-10 | 2011-06-22 | National Center for Scientific Research "Demokritos" Neapoleos & | Per-6-guanidino-, -aminoalkylamino-and -guanidino-alkylamino-cyclodextrins, methods of their synthesis and their use for the compaction of dna and intracellular delivery |
| FR2878853B1 (fr) | 2004-12-07 | 2007-03-16 | Biocydex Soc Par Actions Simpl | Procede d'obtention d'un complexe fluorescent, complexe obtenu et utilisation |
| JP5098015B2 (ja) * | 2005-01-13 | 2012-12-12 | 国立大学法人 名古屋工業大学 | 菌体膜傷害性・抗菌性物質とその利用方法 |
| EP1846006A4 (en) * | 2005-01-28 | 2011-04-20 | Pinnacle Pharmaceuticals Inc | BETA-CYCLODEXTRIN DERIVATIVES AS ANTIBACTERIAL AGENTS |
| WO2007009265A1 (en) | 2005-07-22 | 2007-01-25 | The Governors Of The University Of Alberta Tec Edmonton | NOVEL β-CYCLODEXTRIN-BASED MOLECULES AND DRUG DELIVERY COMPOSITIONS |
-
2006
- 2006-01-27 EP EP06733927A patent/EP1846006A4/en not_active Withdrawn
- 2006-01-27 US US11/342,339 patent/US7737132B2/en not_active Expired - Fee Related
- 2006-01-27 CN CNA2006800101557A patent/CN101151037A/zh active Pending
- 2006-01-27 WO PCT/US2006/002801 patent/WO2006083678A2/en not_active Ceased
- 2006-01-27 MX MX2007010129A patent/MX2007010129A/es unknown
- 2006-01-27 AU AU2006211173A patent/AU2006211173A1/en not_active Abandoned
- 2006-01-27 RU RU2007133709/04A patent/RU2007133709A/ru not_active Application Discontinuation
- 2006-01-27 CA CA002596026A patent/CA2596026A1/en not_active Abandoned
- 2006-01-27 KR KR1020077019399A patent/KR20070101347A/ko not_active Withdrawn
- 2006-01-27 JP JP2007553231A patent/JP2008528761A/ja active Pending
-
2007
- 2007-07-26 ZA ZA200706191A patent/ZA200706191B/xx unknown
- 2007-07-26 IL IL184844A patent/IL184844A0/en unknown
-
2010
- 2010-05-03 US US12/772,740 patent/US20110071108A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101151037A (zh) | 2008-03-26 |
| ZA200706191B (en) | 2010-05-26 |
| KR20070101347A (ko) | 2007-10-16 |
| IL184844A0 (en) | 2008-06-05 |
| US20110071108A1 (en) | 2011-03-24 |
| JP2008528761A (ja) | 2008-07-31 |
| US7737132B2 (en) | 2010-06-15 |
| RU2007133709A (ru) | 2009-03-20 |
| EP1846006A4 (en) | 2011-04-20 |
| EP1846006A2 (en) | 2007-10-24 |
| WO2006083678A3 (en) | 2006-12-14 |
| AU2006211173A1 (en) | 2006-08-10 |
| CA2596026A1 (en) | 2006-08-10 |
| WO2006083678A2 (en) | 2006-08-10 |
| US20060199785A1 (en) | 2006-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007010129A (es) | Derivados de beta-ciclodextrina como agentes antibacteriales. | |
| RU2560846C1 (ru) | Фармацевтические композиции, содержащие сулбактам и ингибитор бета-лактамазы | |
| CN103356612B (zh) | 包含抗菌药以及一种选自麝香草酚、香芹酚的活性物质的药物组合物 | |
| CN110123801A (zh) | 一种多臂aie分子在制备抗菌药物中的用途和抗菌药物 | |
| EP1044006B1 (en) | Use of an antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection | |
| Waitz et al. | Chemotherapeutic evaluation of 5-episisomicin (Sch 22591), a new semisynthetic aminoglycoside | |
| Ehlert et al. | In vitro activity of LY146032 (daptomycin), a new peptolide | |
| CN114129547A (zh) | 香芹酚在提高耐甲氧西林金黄色葡萄球菌对β-内酰胺类抗生素敏感性方面的应用 | |
| US20220409563A1 (en) | Application of compound amino acids in preparation of medicament for improving sensitivity of bacteria to antibiotics | |
| CN107073124A (zh) | 增效的抗微生物剂 | |
| CN113082026A (zh) | 一种青蒿素衍生物在制备多粘菌素抗菌增效剂中的应用 | |
| KR102142870B1 (ko) | 백본-고리형 펩타이드와의 조합물 | |
| Smith et al. | Daptomycin versus vancomycin treatment for Staphylococcus aureus bacteremia in a murine model | |
| CA2972079A1 (en) | A potent synthetic inorganic antibacterial with activity against drug-resistant pathogens | |
| RU2792679C1 (ru) | Бактерицидная фармацевтическая композиция для парентерального применения в форме лиофилизата с эндолизином | |
| US6589993B2 (en) | Treating vancomycin-intermediates and multiresistant staphylococci infection with thiamphenicol or a salt thereof | |
| CN111569079B (zh) | 一种抗葡萄球菌感染的抗体抗生素联合制剂 | |
| WO1995033463A2 (en) | Synergistic antibiotic compositions containing a perphyrin and an antibiotic | |
| PT1458391E (pt) | Um processo para tratamento de infecções bacterianas através do uso de gemifloxacina ou um seu sal e um antibiótico b-lactâmico | |
| Hashizume et al. | Penetration of imipenem and other antibiotics into inflammatory exudate and their efficacy in pseudomonas infection in the rat granuloma pouch model | |
| AU2017235711B2 (en) | Enhanced tulathromycin | |
| Al-Shammari et al. | Potential source of antibiotics extracted from Jordanian soil microbes against MRSA and Acinetobacter baumannii | |
| CN106673989A (zh) | 一种药物组合物及其制备方法和应用 | |
| Lentino et al. | Comparison of in vitro activity of daptomycin, vancomycin and fluoroquinolones in broth and serum against Staphylococcus epidermidis as determined by time-kill kinetics | |
| Fu et al. | Synergistic activity of apalcillin and gentamicin in a combination therapy in experimental Pseudomonas bacteraemia of neutropenic mice |